IM-3050
FAP+ Solid Tumors (Radioligand Therapy)
IND ClearedPhase 1 initiation expected
Key Facts
Indication
FAP+ Solid Tumors (Radioligand Therapy)
Phase
IND Cleared
Status
Phase 1 initiation expected
Company
About Immunome
Immunome is a clinical-stage biotech focused on developing first-in-class and best-in-class targeted oncology therapies, with a core competency in antibody-drug conjugates (ADCs). Founded in 2023 via the merger of Immunome and Morphimmune under Dr. Clay Siegall's leadership, the company has rapidly built a multi-asset pipeline anchored by a late-stage gamma secretase inhibitor (varegacestat) and novel ADCs. Its strategy leverages deep ADC development expertise to systematically optimize novel agents, pursue strategic acquisitions, and address significant unmet needs in solid tumors.
View full company profile